Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events

Introduction Soluble urokinase plasminogen activator receptor (suPAR) is an emerging inflammatory and immune biomarker. Whether suPAR level predicts the presence and the severity of coronary artery disease (CAD), and of incident death and myocardial infarction (MI) in subjects with suspected CAD, is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2014-10, Vol.3 (5), p.e001118-n/a
Main Authors: Eapen, Danny J., Manocha, Pankaj, Ghasemzadeh, Nima, Patel, Riyaz S., Al Kassem, Hatem, Hammadah, Muhammad, Veledar, Emir, Le, Ngoc‐Anh, Pielak, Tomasz, Thorball, Christian W., Velegraki, Aristea, Kremastinos, Dimitrios T., Lerakis, Stamatios, Sperling, Laurence, Quyyumi, Arshed A.
Format: Article
Language:English
Subjects:
biomarker
cardiovascular outcomes
Cohort Studies
Coronary Angiography - methods
Coronary Artery Disease - blood
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - mortality
coronary heart disease
C‐reactive protein
Female
Humans
inflammation
Inflammation Mediators - blood
Male
Original Research
Predictive Value of Tests
Proportional Hazards Models
Receptors, Urokinase Plasminogen Activator - blood
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Solubility
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Soluble urokinase plasminogen activator receptor (suPAR) is an emerging inflammatory and immune biomarker. Whether suPAR level predicts the presence and the severity of coronary artery disease (CAD), and of incident death and myocardial infarction (MI) in subjects with suspected CAD, is unknown. Methods and Results We measured plasma suPAR levels in 3367 subjects (67% with CAD) recruited in the Emory Cardiovascular Biobank and followed them for adverse cardiovascular (CV) outcomes of death and MI over a mean 2.1±1.1 years. Presence of angiographic CAD (≥50% stenosis in ≥1 coronary artery) and its severity were quantitated using the Gensini score. Cox's proportional hazard survival and discrimination analyses were performed with models adjusted for established CV risk factors and C‐reactive protein levels. Elevated suPAR levels were independently associated with the presence of CAD (P
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.114.001118